(NASDAQ: CV) Capsovision's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.97%.
Capsovision's revenue in 2025 is N/A.On average, 4 Wall Street analysts forecast CV's revenue for 2025 to be $683,583,182, with the lowest CV revenue forecast at $650,418,179, and the highest CV revenue forecast at $696,839,815. On average, 4 Wall Street analysts forecast CV's revenue for 2026 to be $952,838,040, with the lowest CV revenue forecast at $906,603,777, and the highest CV revenue forecast at $971,341,114.
In 2027, CV is forecast to generate $2,552,346,801 in revenue, with the lowest revenue forecast at $2,428,446,470 and the highest revenue forecast at $2,601,906,933.